

Evaluation of the therapeutic response of hepatitis C in coinfecting patients (HIV/HCV): a study of cases from a hospital for chronic liver diseases in the Eastern Brazilian Amazon

Ivanete do Socorro Abraçado Amaral^{[1],[2]}, Lizomar de Jesus Maués Pereira Mória^{[1],[2],[3]},
Maria Silvia de Brito Barbosa^{[1],[3]}, Samia Demachki^[3], Marialva Tereza Ferreira de Araújo^[3]
and Manoel do Carmo Soares^[4]

[1]. Programa de Hepatopatias Crônicas, Fundação Santa Casa de Misericórdia do Pará, Belém, PA. [2]. Centro de Ciências Biológicas e de Saúde, Universidade do Estado do Pará, Belém, PA. [3]. Faculdade de Medicina, Universidade Federal do Pará, Belém, PA. [4]. Laboratório de Biologia Molecular, Instituto Evandro Chagas, Fundação Nacional de Saúde, Ministério da Saúde, Belém, PA.

ABSTRACT

Introduction: The aim of this study was to evaluate the therapeutic response of hepatitis C in patients coinfecting with human immunodeficiency virus (HIV-1). **Methods:** A retrospective study of 20 patients coinfecting with HIV-1/HCV who were treated in the outpatient liver clinic at the Sacred House of Mercy Foundation Hospital of Pará (*Fundação Santa Casa de Misericórdia do Pará* - FSCMPA) from April 2004 to June 2009. Patients were treated with 180µg PEG interferon-α2a in combination with ribavirin (1,000 to 1,250mg/day) for 48 weeks. The end point was the sustained virological response (SVR) rate (HCV RNA negative 24 weeks after completing treatment). **Results:** The mean age of the patients was 40±9.5 years, of which 89% (n=17) were male, and the HCV genotypes were genotype 1 (55%, n=11/20), genotype 2 (10%, n=2/20) and genotype 3 (35%, n=7/20). The mean CD4+ lymphocyte count was 507.8, and the liver fibrosis stages were (METAVIR) F1 (25%), F2 (55%), F3 (10%) and F4 (10%). The early virological response (EVR) was 60%, the end-of-treatment virological response (EOTVR) was 45% and the SVR was 45%. **Conclusions:** The median HCV viral load was high, and in 85% of cases in which highly active antiretroviral therapy (HAART) was used, none of the patients with F3-F4 fibrosis responded to treatment. Of the twenty patients treated, 45% achieved SVR and 45% achieved EOTVR. Studies that include cases from a wider region are needed to better evaluate these findings.

Keywords: HIV/HCV coinfection. Human immunodeficiency virus. Hepatitis C treatment.

INTRODUCTION

With the introduction of highly active antiretroviral therapy (HAART) in 1996, there have been many important changes in the natural history of human immunodeficiency virus-1 (HIV-1) infection¹. Studies show that the progression of liver disease caused by the hepatitis C virus (HCV) is more severe and progresses more rapidly in people coinfecting with human immunodeficiency virus/hepatitis C virus (HIV/HCV) compared with those only infected with HCV². This effect can be explained by the high viremia and cytotoxicity of HCV, resulting in accelerated fibrosis processes, increased risk of cirrhosis, increased morbidity and mortality due to terminal liver disease, earlier development of hepatocellular carcinoma and increased incidence of liver toxicity associated with the use of antiretrovirals³. HIV-coinfection is included among the factors that may contribute to the accelerated progression of

liver disease in patients with hepatitis C^{4,5}. The presence of HIV appears to alter the natural history of HCV infection in terms of its progression towards hepatic cirrhosis, hepatocellular carcinoma and liver failure⁶. In a cohort study of a group of coinfecting patients, there was an increase in the progression of liver fibrosis and its evolution to cirrhosis compared with a mono-infected group of HCV patients⁷.

These studies illustrate the importance of treating these coinfecting patients. Recently, studies have shown that the successful treatment of hepatitis C drastically reduces the complications of pre-existing liver disease⁸. Treatment is especially recommended for patients with a high probability of achieving sustained virological response (SVR), for patients with genotype 2 or genotype 3 and for patients infected with genotype 1 who have a low viral load (less than 400,000 to 500,000IU/ml)⁹. The treatment of choice for patients coinfecting with HIV/HCV is PEG-interferon^{10,11} in combination with ribavirin (RBV) at the same doses used in HIV-negative patients, independent of the viral genotype, with the presence of mild to severe fibrosis (F1 by the METAVIR or the Brazilian Society of Pathology classifications)¹². The early virological response (EVR) and sustained virological response (SVR) rates are, however, lower in HIV-positive patients than in HIV-negative patients¹³.

Address to: Dra. Ivanete do Socorro Abraçado Amaral. FSCMPA/UEPA. Rua Oliveira Belo 395, 66050-380 Belém, PA, Brasil.

Phone: 55 91 3242-9022; 55 91 9118-0222; Fax: 55 91 3210-2299

e-mail: ivanetesaa@ufpa.br

Received in 12/02/2012

Accepted in 21/11/2012

METHODS

Case studies

This was a retrospective study of patients with HIV-HCV coinfection using the research protocol containing demographic information, laboratory tests, histopathology of liver biopsy, early virological response, end-of-treatment virological response (EOTVR), sustained virological response (SVR) and non-responders to treatment with 180µg PEG-Interferon (PEG-IFN) α -2a in combination with ribavirin (1,000mg for patients under 75kg and 1,250mg for patients \geq 75kg). Twenty patients being treated at the outpatient liver clinic at the Sacred House of Mercy Foundation Hospital of Pará (*Fundação Santa Casa de Misericórdia do Pará - FSCMPA*, Belém, State of Pará, Brazil) who met the indication criteria for treatment according to the Brazilian Ministry of Health (the inclusion criteria) were selected. EVR was considered to be a reduction \leq 2 log of the baseline levels of hepatitis C virus ribonucleic acid (HCV RNA) at week 12, and EOTVR and SVR were defined as undetectable serum levels of HCV RNA at weeks 48 and 72, respectively. The patients who participated in the study were 15 years of age or older, both male and female, serologically confirmed HIV carriers (ELISA + indirect immunofluorescence or western blot), positive for anti-HCV antibodies by enzyme-linked immunosorbent assay (ELISA) and confirmed by reverse transcription-polymerase chain reaction (RT-PCR). Samples were forwarded to the HIV reference services in the State of Pará. All of the patients were treated at the outpatient clinic of the FSCMPA hospital between April 2004 and June 2009. The following tests were performed: serum aminotransferase levels were assessed at the FSCMPA laboratory using an auto-analyzer. The HIV viral load and cluster of differentiation 4 (CD4)+ T-lymphocyte levels were assessed at the Central Laboratory of the State of Pará (*Laboratório Central do Estado do Pará - LACEN-PA*). The serological markers for viral hepatitis (HBsAg, anti-HCV) were used and molecular biology tests (HCV genotyping and HCV viral load) performed at the Laboratory of Serology and Molecular Biology, Hepatology Section, Evandro Chagas Institute. The patients received histological evaluations via liver biopsy prior to treatment (when indicated), which were performed at FSCMPA by professionals in the chronic liver diseases program in the aforementioned hospital as a routine service. METAVIR scores were used for staging fibrosis and hepatic inflammatory activity. The data were subjected to statistical analysis. The analysis, organization and tabulation of the study data were generated using the software EPI INFO (version 6.2) and the software Biostat 5.0 (Ayres et al., 2008). The control group included 49 patients treated at FSCMPA, only with HCV infection who received PEG interferon and ribavirin.

Ethical considerations

The Ethics Committee at *Fundação Santa Casa de Misericórdia do Pará* approved the study (Resolution n. 196/96-CNS/MS, Item VII, 13d).

RESULTS

Only twenty patients who were selected to receive treatment with 180µg PEG-IFN α -2a in combination with ribavirin were studied. Eighteen (90%) patients were male, 5/20 (25%) were married, 14/20 (70%) were single and 1/20 (5%) was divorced. All of the patients had CD4+ lymphocyte counts above 200 cells/mm³, 18/20 (90%) patients were on antiretroviral therapy and 7/20 (35%) patients had undetectable levels of serum HIV RNA. The biochemical data, molecular biology tests and stage of fibrosis based on the METAVIR classification are summarized in **Table 1**. Early virological response was observed in 12/20 (60%) patients, EOTVR in 9/20 (45%) patients and SVR in 9/20 (45%) patients. With respect to HCV genotype and SVR, there was no statistically significant correlation. When SVR was compared with HCV RNA levels, there was also no statistically significant correlation. For aminotransferase levels, only patients whose alanine aminotransferase (ALT) levels were 2.5 times the upper limit of normal (ULN) responded to treatment (SVR), $p < 0.05$ (**Table 2**).

TABLE 1 - Epidemiologic and laboratory group and control liver outpatient clinic Fundação Santa Casa de Misericórdia do Pará FSCMPA of the period April 2007 to April 2009.

Variables	HIV/HCV (n=20) (%)	HCV (n=49) (%)
Origin: Belém	17/20 (85.0)	39/49 (79.5)
Gender: male	18/20 (90.0)	38/49 (77.5)
Age (Y) (n=)		
mean	41.6	52.0
SD	± 10	± 9.97
Genotype 1 (n=)	11/20 (55.0)	44/49 (89.7)
Genotype 2 (n=)	2/20 (10.0)	3/49 (6.1)
Genotype 3 (n=)	7/20 (35.0)	2/49 (4.0)
ALT (UI/L) (mean)	90UI/L	21,490UI/ml
AST (UI/L) (mean)	71UI/L	89,480UI/ml
CD4+ cels/mm ³ (mean)	507.8	—
Taking HAART	18/20 (90.0)	—
HIV-RNA undetectable (%)	13/20 (65.0)	—
HIV-RNA copies/ml (median)	40	—
HCV RNA UI/mL (median)	850,000	491,181
Stages of fibrosis (METAVIR)		
F0	0	0
F1	4/20 (20.0)	4/49 (8.2)
F2	12/20 (60.0)	24/49 (49.0)
F3	2/20 (10.0)	12/49 (24.5)
F4	2/20 (10.0)	9/49 (18.3)
SVR	9/20 (45.0)	25/49 (51.0)

FSCMPA: *Fundação Santa Casa de Misericórdia*; HIV: human immunodeficiency virus; HCV: hepatitis C virus; SD: standard deviation; HAART: highly active antiretroviral therapy; SVR: sustained virological response; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CD4: cluster of differentiation 4; RNA: ribonucleic acid; METAVIR: score-histological features of liver biopsy according to the Metavir scoring system.

TABLE 2 - The biochemical data, molecular biology tests and stage of fibrosis based on the METAVIR classification.

Variables	SVR	No SVR	P
HCV-RNA			1.0*
≥ 400,000UI/ml	9	0	
≤ 400,000UI/ml	0	0	
HCV genotype			0.6**
1	4	5	
not a 1	5	4	
ALT			0.01*
≥ 2xULN	8	5	
≤ 2xULN	0	7	
METAVIR (F)			0.04**
F1 F2	9	7	
F3 F4	0	4	

METAVIR: score histological features of liver biopsy according to the Metavir scoring system; **SVR:** sustained virological response; **HCV-RNA:** hepatitis C virus-ribonucleic acid; **HCV:** hepatitis C virus; **ALT:** alanine aminotransferase; **ULN:** upper limit of normal; * Fisher's exact test; ** chi-squared test.

DISCUSSION

The reasons for treating hepatitis C in patients coinfecting with HIV/HCV vary. In these patients, HAART is more hepatotoxic, the evolution of liver disease is faster and the risk of developing hepatocellular carcinoma is higher¹⁴. Successful treatment reduces the complications of liver disease. Unfortunately, many patients do not meet the prerequisites for inclusion in the scheme for HCV antiviral treatment. The virologic response rates found were similar to those of large studies, although with a smaller sample. PRESCO (Peginterferon Ribavirin España Coinfection Trial Study Group) study with larger samples involving 389 patients, found SVR rate of 50% and LAGUNO (Infectious Diseases Service the Hospital Clinic, Barcelona, Spain (Montserrat Laguno) study with a smaller sample of 52 patients, found SVR rate of 44%. When ALT levels are evaluated, no patient had normal ALT level, similar to the large studies. When grouped together ALT levels greater than 2.5 x ULN and below this limit and relating them to the SVR, significant correlation was observed among patients with values above 2x ULN. HCV genotypes 2 or 3, low HCV viral load, absence of liver cirrhosis, age younger than 40 years old, elevated ALT levels, elevated CD4 counts, and low or undetectable plasma HIV-RNA, are the best candidates for HCV treatment in coinfecting group of HIV/HCV¹⁵. The biochemical response in HCV-HIV co-infected patients is not a good marker of SVR. In the, APRICOT (Aids Pegasys Ribavirin International Coinfection Trial), RIBAVIC, LAGUNO and PRESCO studies¹⁶⁻¹⁹, patients were using the HAART scheme in more than 70% of the cases, the mean CD4+ lymphocyte counts were above 500 cells/mm³ and the ALT levels were normal in only 16% of cases in the RIBAVIC study. In the RIBAVIC (Ribavirin Study Team (France) and PRESCO studies, the stages of fibrosis were measured by the METAVIR classification (F3/F4) and were reported in 28 and 39% of cases, respectively. These data are similar to the presented study (FSCMPA), even with the

smaller sample size. In a study using PEG-IFN and ribavirin in 68 coinfecting patients, the researchers found an SVR rate of 35%²⁰, which is lower than the rate found in the present study. In the PRESCO study, in which 28% of the patients had F3-F4 fibrosis, the response rate at the end of treatment and SVR were 67% and 50%, respectively, which is higher than the present study; however, the sample size was much larger.

The RIBAVIC study, which included 194 patients, reported that 39% of patients had F3-F4 fibrosis, with EOTVR and SVR rates of 35% and 27%, respectively. In the APRICOT study, which included 289 patients, 15% of whom had hepatic cirrhosis, the EOTVR and SVR rates were 49% and 40%, respectively. The SVR results reported in the present study were similar to those found in the LAGUNO study (**Table 3**). Studies have shown that the percentage of SVR is higher, either in mono-infected or coinfecting patients, for patients infected with genotypes 2 and 3 and when pre-treatment HCV RNA levels are lower²¹. Patients coinfecting with HIV/HCV have higher levels of HCV RNA²² in the present study, only 11.2% of patients presented with HCV RNA levels below 400,000IU/ml. Importantly, in the present study, patients with a stage of severe fibrosis (F3, F4), did not achieve a sustained virological response to treatment. Although the sample size in the present study was small, several studies have shown that one of the predictive factors for being non-responsive to treatment is an advanced stage of fibrosis¹⁵. In the control group is shown that the patients respond to anti HCV similarly, slightly worse compared to mono-infected. Is important to select the patients coinfecting for anti HCV treatment in order that achieve a SVR similarity mono-infected patients.

TABLE 3 - Studies on hepatitis C treatment with PEG-IFN and ribavirin in patients coinfecting with HIV/HCV*.

	APRICOT	RIBAVIC	LAGUNO	PRESCO	FSCMPA
Number of patients	289	184	52	389	20
Hepatic cirrhosis (%)	15	39 (F3-F4)	19	28 (F3-F4)	20 (F3-F4)
Normal ALT (%)	0	16	0	0	0
Mean CD4+ Count	520	477	570	546	507.8
HAART scheme (%)	83	83	94	74	89.5
UIVD	62	80	75	70	47.4
Discontinuation due to AE (%)	25	17	17	9	15.78
EOTVR Rate	49	35	52	67	45
SVR Rate	40	27	44	50	45

*Table modified from HepatologyTextbook. Mauss S, et al. 2009. Available from: www.hepatologytextbook.com/; **PEG-IFN:** Peginterferon; **HIV/HCV:** human immunodeficiency virus/hepatitis C virus; **APRICOT:** Aids Pegasys Ribavirin International Coinfection Trial; **RIBAVIC:** Ribavirin Study Team (France); **LAGUNO:** Infectious Diseases Service the Hospital Clinic, Barcelona, Spain (Montserrat Laguno); **PRESCO:** Peginterferon Ribavirin España Coinfection Trial Study Group; **FSCMPA:** Fundação Santa Casa de Misericórdia do Pará; **ALT:** alanine aminotransferase; **CD4:** cluster of differentiation 4; **HAART:** highly active antiretroviral therapy antiretroviral therapy; **UIVD:** Use of intravenous drugs; **AE:** adverse effects. **EOTVR:** end of treatment virological response; **SVR:** sustained virological response.

Patients coinfecting with HIV/HCV can be treated following the indication and contraindication criteria. The virological responses, even with the small sample size in the present study, were similar to those reported in previous studies. A larger sample size is needed to improve this regional assessment.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

REFERENCES

- Gonzales SA, Talal AH. Hepatitis C virus in human immunodeficiency virus-infected individuals: an emerging comorbidity with significant implications. *Semin Liver Dis* 2003; 23:149-166.
- Bonacini M, Puoti M. Hepatitis C in patients with HIV-infection. *Arc Intern Med* 200; 160:3365-3373.
- Vallet-Pichard A, Pol S. Natural history and predictors of severity of chronic Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. *J Hepatol* 2006; 44:S28-S34.
- Eyster EM, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. *Blood J Hematol* 1994; 84:1020-1023.
- Martinez-Sierra C, Arizcorreta A, Díaz F, Roldán R, Martín-Herrera L, Pérez-Guzmán E, et al. Progresión of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfecting with hepatitis C virus and human immunodeficiency virus. *Clin Infect Dis* 2003; 36:491-498.
- Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. *The Lancet* 2000; 356:1800-1805.
- Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, David L, Thomas et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index. *Journal of Hepatology* 2005; 43:78-84.
- Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H. *Hepatology: a clinical textbook* [Internet] Germany: Flying Publisher. 2009; [Cited 2012 December 12]. Available from: www.hepatologytextbook.com/.
- Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. *HIV Med* 2008; 9:82-88.
- Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al. Statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. *J Hepatol* 2005; 42:615-624.
- Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in a urban population: low eligibility for interferon treatment. *Clin Infect Dis* 2003; 36:97-100.
- Mello ES, Alves VAF. Chronic hepatitis C: pathological anatomy. *Braz J Infect Dis* 2007; 11 (suppl I):28-32.
- Layden-Aimer JE, Layden TJ. Viral kinetics in hepatitis C virus: special patient populations. *Seminars Liver Dis* 2007; 11 (suppl I): 28-32.
- Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, et al. Correlates of hepatitis C virus infections among drug users. *Medicine (Baltimore)* 1995; 74:212-220.
- Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Gonzalez-Garcia J, Lazzarin A, Carosi G, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. *N Engl J Med* 2004; 351:438-450.
- Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiane F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. *JAMA* 2005; 293:1323.
- Laguno M, Cifuentes C, Murillas J, Veloso S, Larrousse M, Payeras A, et al. Randomized trial comparing pegylated interferon 2b versus pegylated interferon 2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients. *Hepatology* 2009; 49:22-31.
- Núñez M, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The Presco Trial. *Aids Res Hum Retroviruses* 2007; 23:972-982.
- Perez-Olmeda M, Romero M, Gonzalez J, Castro A, Arribas JR, Pedreira J, et al. Pegylated IFN-alfa-2b plus ribavirin as therapy for chronic hepatitis C, in HIV-infected patients. *AIDS* 2003; 17:1023-1028.
- Thomas DL. Options for treatment of hepatitis C in HIV-infected persons. *J Hepatol* 2006; 44:S40-S43.
- Beld M, Penning M, Lukashov V, McMorro M, Roos M, Pakker N, et al. Evidence that both HIV-induced immunodeficiency enhance HCV Replication among HCV Seroconverters. *Virology* 1998; 244:504-512.
- Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. *Hepatology* 1996; 24:289-293.